Zacks: Analysts Anticipate Fennec Pharmaceuticals Inc (NASDAQ:FENC) to Post -$0.14 EPS
Equities analysts predict that Fennec Pharmaceuticals Inc (NASDAQ:FENC) will announce earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Fennec Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.13). Fennec Pharmaceuticals also reported earnings per share of ($0.14) in the same quarter last year. The company is expected to report its next quarterly earnings report on Monday, August 12th.
On average, analysts expect that Fennec Pharmaceuticals will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.57). For the next year, analysts expect that the company will report earnings of $1.45 per share, with EPS estimates ranging from ($0.50) to $3.39. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01.
Shares of NASDAQ FENC traded down $0.16 during midday trading on Friday, reaching $3.37. 700 shares of the stock were exchanged, compared to its average volume of 58,038. The company has a market capitalization of $66.36 million, a P/E ratio of -6.77 and a beta of -0.24. Fennec Pharmaceuticals has a twelve month low of $3.47 and a twelve month high of $11.81.
Institutional investors and hedge funds have recently bought and sold shares of the business. venBio Select Advisor LLC raised its holdings in shares of Fennec Pharmaceuticals by 8.1% in the fourth quarter. venBio Select Advisor LLC now owns 1,105,999 shares of the company’s stock valued at $7,056,000 after buying an additional 83,333 shares during the last quarter. BlackRock Inc. boosted its position in Fennec Pharmaceuticals by 0.4% during the 4th quarter. BlackRock Inc. now owns 562,216 shares of the company’s stock worth $3,588,000 after acquiring an additional 2,429 shares during the last quarter. United Services Automobile Association raised its stake in shares of Fennec Pharmaceuticals by 87.4% during the 4th quarter. United Services Automobile Association now owns 154,190 shares of the company’s stock worth $984,000 after purchasing an additional 71,922 shares in the last quarter. Oxford Asset Management LLP raised its stake in Fennec Pharmaceuticals by 490.2% in the 1st quarter. Oxford Asset Management LLP now owns 84,750 shares of the company’s stock valued at $411,000 after acquiring an additional 70,391 shares during the period. Finally, Vanguard Group Inc raised its stake in Fennec Pharmaceuticals by 7.1% in the 3rd quarter. Vanguard Group Inc now owns 43,488 shares of the company’s stock valued at $357,000 after acquiring an additional 2,868 shares during the period. Hedge funds and other institutional investors own 48.46% of the company’s stock.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Further Reading: What type of investment options does a Roth IRA provide?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.